Evidence map›Paper›PMID 41454038›Full record

ArticleNPJ digital medicine2025

Clinically informed semi-supervised learning improves disease annotation and equity from electronic health records: a glaucoma case study.

Mousa Moradi, Rishi Shah, Asahi Fujita, Niloufar Bineshfar, Daniel M Vu, Kanza Aziz, Daniel L Liebman, Saber Kazeminasab Hashemabad, Mengyu Wang, Tobias Elze and 2 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mousa MoradiHarvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Rishi ShahHarvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Asahi FujitaMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Niloufar BineshfarMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Daniel M VuMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Kanza AzizMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Daniel L LiebmanMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Saber Kazeminasab HashemabadHarvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Mengyu WangHarvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Tobias ElzeHarvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Mohammad Eslami *Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Nazlee Zebardast *Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA. Nazlee_Zebardast@MEEI.HARVARD.EDU.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Personalizing Glaucoma Diagnosis by Disease Specific Patterns and Individual Eye AnatomyR01EY030575 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ELZE, TOBIAS · 2019 to 2023
$2.4M
Developing Population-Generalizable Deep Learning Models for Automated Glaucoma ScreeningR01EY036222 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Mengyu Wang · 2024 to 2026
$2.0M
Personalizing Circumpapillary Retinal Nerve Fiber Layer Thickness Norms for GlaucomaR21EY035298 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI WANG, MENGYU · 2023 to 2023
$557k
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY030575NEI NIH HHS R01 EY036222NEI NIH HHS R21 EY035298NIH HHS R01 EY036222NIH HHS R21 EY035298
6 · The paper itself

Abstract

Clinical notes represent a vast but underutilized source of information for disease characterization, whereas structured electronic health record (EHR) data such as ICD codes are often noisy, incomplete, and too coarse to capture clinical complexity. These limitations constrain the accuracy of datasets used to investigate disease pathogenesis and progression and to develop robust artificial intelligence (AI) systems. To address this challenge, we introduce Ci-SSGAN (Clinically Informed Semi-Supervised Generative Adversarial Network), a novel framework that leverages large-scale unlabeled clinical text to reannotate patient conditions with improved accuracy and equity. As a case study, we applied Ci-SSGAN to glaucoma, a leading cause of irreversible blindness characterized by pronounced racial and ethnic disparities. Trained on a demographically balanced subset of 349587 unlabeled ophthalmology notes and 2954 expert-annotated notes (drawn from an institutional corpus of 2.1 million notes), Ci-SSGAN achieved 0.85 accuracy and 0.95 AUROC, representing a 10.19% AUROC improvement compared to ICD-based labels (0.74 accuracy, 0.85 AUROC). Ci-SSGAN also narrowed subgroup performance gaps, with F1 gains for Black patients (+ 0.05), women (+ 0.06), and younger patients (+ 0.033). By integrating semi-supervised learning and demographic conditioning, Ci-SSGAN minimizes reliance on expert annotations, making AI development more accessible to resource-constrained healthcare systems.

Identifiers

PMID41454038
PMCPMC12847826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.